Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Susumu S. Kobayashi, MD, PhD"'
Autor:
Ikei S. Kobayashi, MD, PhD, William Shaffer, MS, Hollis Viray, MD, Deepa Rangachari, MD, Paul A. VanderLaan, MD, PhD, Susumu S. Kobayashi, MD, PhD, Daniel B. Costa, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 1, Pp 100614- (2024)
Introduction: Mechanisms of resistance to EGFR exon 20 insertion mutation active inhibitors have not been extensively studied in either robust preclinical models or patient-derived rebiopsy specimens. We sought to characterize on-target resistance mu
Externí odkaz:
https://doaj.org/article/9d6f86ae7ca94cdea9028f4d32112c40
Autor:
Yosuke Kagawa, MD, Takuma Hayashida, MS, Jie Liu, BS, Shunta Mori, MD, Hiroki Izumi, MD, PhD, Shogo Kumagai, MD, PhD, Hibiki Udagawa, MD, PhD, Noboru Hattori, MD, PhD, Koichi Goto, MD, PhD, Susumu S. Kobayashi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 3, Pp 100462- (2023)
Introduction: EGFR exon 20 insertion mutations account for 5% to 10% of EGFR-mutated NSCLC. CLN-081 (formerly known as TAS6417), a novel covalent EGFR tyrosine kinase inhibitor, exhibits pan-mutation selective efficacy, including exon 20 insertions,
Externí odkaz:
https://doaj.org/article/e3d98b0bb20a49d68b4a9a9c19b6c29e
Autor:
Pedro E.N.S. Vasconcelos, MS, Ikei S. Kobayashi, MD, PhD, Susumu S. Kobayashi, MD, PhD, Daniel B. Costa, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 3, Pp 100105- (2021)
Introduction: EGFR exon 20 insertion mutations account for 10% of all EGFR mutations and are mostly insensitive to approved EGFR tyrosine kinase inhibitors (EGFR TKIs). Novel EGFR TKIs have been developed or repurposed for these mutants. A limited nu
Externí odkaz:
https://doaj.org/article/000298c3a25d4651aa115a4e30b75810
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 3, Pp 100133- (2021)
Externí odkaz:
https://doaj.org/article/ffb7e72e52284031b6b4ee300cab554a
Autor:
Andrew J. Piper-Vallillo, MD, Brian T. Halbert, MD, Deepa Rangachari, MD, Susumu S. Kobayashi, MD, PhD, Daniel B. Costa, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 1, Iss 4, Pp 100071- (2020)
Externí odkaz:
https://doaj.org/article/ee48ab2a7c484a638016c32f7d0ed184
Autor:
Pedro E.N.S. Vasconcelos, MS, Carol Gergis, MS, Hollis Viray, MD, Andreas Varkaris, MD, PhD, Masanori Fujii, MD, PhD, Deepa Rangachari, MD, Paul A. VanderLaan, MD, PhD, Ikei S. Kobayashi, MD, PhD, Susumu S. Kobayashi, MD, PhD, Daniel B. Costa, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 1, Iss 3, Pp 100051- (2020)
Introduction: The EGFR-A763_Y764insFQEA is a unique exon 20 insertion mutation (∼5% to 6% of exon 20 insertions), which, at the structural and enzyme kinetic level, more closely resembles EGFR tyrosine kinase inhibitor (TKI)–sensitizing mutants,
Externí odkaz:
https://doaj.org/article/b0e73be55f654db78b7ddafa36ce97a9